Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

There is limited information about the effect of PTH(1-84) after 18 months and limited data about the impact of compliance on response to anabolic therapy.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and people over 80, women only.

Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension.

Thereafter, they were followed for 12 additional months after discontinuation of treatment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and open-label study.

The participants were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.

Nothing was hidden in this open-label Parathyroid Hormone (PTH 1-84) study: the participants and staff both knew the treatment.

Endpoints examined included changes in BMD and biochemical markers.

What Was Measured

PubMed files the paper under topics including Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Femur Neck, Hip Joint and Lumbar Vertebrae.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Parathyroid Hormone (PTH 1-84).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.